Literature DB >> 22409497

Drugs for Alzheimer's disease.

James M Ritter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22409497      PMCID： PMC3376427          DOI： 10.1111/j.1365-2125.2012.04217.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

Review 1.  Acetylcholinesterase inhibitors in Alzheimer's disease.

Authors:  B M McGleenon; K B Dynan; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  A protein factor essential for microtubule assembly.

Authors:  M D Weingarten; A H Lockwood; S Y Hwo; M W Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

Review 3.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Authors:  Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

4.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

5.  Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

Authors:  M Nistor; M Don; M Parekh; F Sarsoza; M Goodus; G E Lopez; C Kawas; J Leverenz; E Doran; I T Lott; M Hill; E Head
Journal:  Neurobiol Aging       Date:  2006-08-09       Impact factor: 4.673

Review 6.  Alzheimer disease and Down syndrome: factors in pathogenesis.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2005-03       Impact factor: 4.673

7.  Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial.

Authors:  Orestes V Forlenza; Breno S Diniz; Márcia Radanovic; Franklin S Santos; Leda L Talib; Wagner F Gattaz
Journal:  Br J Psychiatry       Date:  2011-05       Impact factor: 9.319

8.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.

Authors:  D Games; D Adams; R Alessandrini; R Barbour; P Berthelette; C Blackwell; T Carr; J Clemens; T Donaldson; F Gillespie
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

Review 9.  Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches.

Authors:  Bianca Van Broeck; Christine Van Broeckhoven; Samir Kumar-Singh
Journal:  Neurodegener Dis       Date:  2007-07-06       Impact factor: 2.977

10.  Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease.

Authors:  E Masliah; A Sisk; M Mallory; L Mucke; D Schenk; D Games
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167
View more
  1 in total

1.  Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease.

Authors:  Kun Han; Ning Jia; Ji Li; Li Yang; Lian-Qiu Min
Journal:  Mol Med Rep       Date:  2013-07-25       Impact factor: 2.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.